|
Friday
September 27, 2002
• Cytogen to Hold Special Meeting of Stockholders to Approve
a Reverse Stock Split
•
Zyomyx Announces Issuance of Fourth U.S. Patent
•
OGS
Interim Results For The Six Months Ending 30 June 2002
• Search for 'Efficiency' Prompts Caliper to Lay Off
10 Percent of Workforce
• Celera
and Applied Biosystems Select IBM Supercomputers and Services for
Drug Discovery and Knowledge Businesses
• Inhibitors of HIV Replication Identified Using Ciphergen
Biosystems Technology
• Nonlinear Dynamics and Amersham Biosciences
Announce Further Collaboration by Signing Exclusive Software Deal For
ImageQuant TL
• GeneProt
Has Started the Industrial-Scale Proteomic Study of Diseases Detectable
in Cerebrospinal Fluid
• Fred
Hutchinson Receives $12.7 Million to Lead Prostate-Cancer Research
Consortium
• Matritech Announces the Return of Richard Sandberg
to its Board of Directors
• Eprogen
Signs OEM & License Agreement with Beckman Coulter for Proteomics
Technology
• Biotech Boosters Deny Grim Future
Wednesday
September 25, 2002
• Beckman Coulter to Offer Nanoliter Dispensing Capabilities
Miniaturization to Meet Demands of Drug Discovery, Proteomics and Genomics
Markets
•
ActivX
Announces Promotion of Jonathan Burbaum, Ph.D.
• SGI
Enables Groundbreaking Biomedical Research at National Cancer Institute
Supercomputing Center
• GeneData Introduces Expressionist™ 4.0 Suite, a Modular
System for Quality Control, Curation, and Analysis of Microarray Data
• Serenex and Chiron Sign Drug Discovery Collaboration:
Serenex's Proteome Mining Technology to Enhance Chiron's
Drug Development Strategies
Monday
September 23, 2002
• OGS Announces Acceptance of Validated Protein Targets for
Respiratory Disease By Bayer
• Progenics
and Cytogen Report Positive Preclinical Results for Experimental
Prostate Cancer Drug
• IGEN Launches New M-SERIES® Analyzer for Life Science
Friday
September 20, 2002
• OGS and FDA to Evaluate Protein Markers Predictive of Drug
Toxicity
•
SYN X Pharma Receives U.S. Patent for its Alzheimer's Disease
Diagnostic Technology - Simple Blood Test One Step Closer to Commercialization.
• Report:
Drug Discovery and Development Reaching New Heights with Potential Wide
Use Of Emerging Metabolomic Technologies
• PharmaGap: Mr Robert Cameron to Provide Investor Relations
Services
• MDS
Reports Third Quarter 2002 Results Earnings growth reflects continued
strength of Life Sciences businesses
Wednesday
September 18, 2002
•
Genomic
Solutions To Appeal Nasdaq Delisting Notice
•
LSBC Creates New Business Units to Reflect Commercial Opportunities
• Molecular Devices Introduces IonWorks™ HT System for
High-Throughput Ion Channel Screening
• Emerging
Technologies To Be Presented at IBC's 13th International Antibody
Engineering Conference December 1-4, 2002 San Diego, CA.
• The Economist Names ISB's Dr. Leroy Hood Innovation
in Bioscience Award Winner
• IDG's
Bio-IT World Publishes First Buyer's Guide Focused on Information Technology
and Informatics for the Life Sciences
Tuesday
September 17, 2002
• Report: Structural Proteomics will Accelerate Drug Discovery
and Reduce Its Cost, but Advances in Automation and Information Technology
Are Required for Full Development and Exploitation
• Indiana
Proteomics Consortium Adds Broad Business, Venture Capital Expertise
with New Board Members: Gill, Hunt, Kissinger join partnership between
Indiana and Purdue, Eli Lilly and Company
• GPC Biotech Adopts Expanded Corporate Governance Principles
• LSBC Files for Orphan Drug Status on Plant-Produced Human
Alpha-Galactosidase A
•
Boston
Biomedica Announces the Release for Sale of its First Pressure Cycling
Technology (PCT) Product -- Targets Billion Dollar Genomics/Proteomics
Markets
• IDEC
and Caprion
Announce Drug Discovery Collaboration in Oncology
•
SRI
Protein Phosphatases Drug Discovery Conference to Take Place September
26-27, 2002 in Philadelphia, PA.
Monday
September 16, 2002
• Frost & Sullivan New Research: Proteomics and Drug
Discovery Fuels the Life Science Mass Spectrometry Markets
•
Cellzome Appoints Dr. David Brown as President and CEO
• Applied Molecular Evolution Signs Kauffman Licensing
Agreement with NascaCell
• Cytogen
Restructures AxCell Subsidiary to Support Company Focus on Oncology
Product Marketing and Development
• Ribonomics and MBL Announce Strategic Alliance for
Diagnostics
Friday
September 13, 2002
• GeneBio and Bruker Daltonics Announce Worldwide Distribution
Agreement for Melanie 2D Gel Proteomics Analysis Software
Thursday
September 12, 2002
•
Chemicon
Launches New ATA100 Tissue Array Instrument
•
Molecular Diagnostics Commences Commercialization in China: Leading
Edge Laboratory in China to Offer Complete InPath System For Patient Care
• EraGen Biosciences is Awarded Grant Funding to Develop Rapid
Genetic Tests For Cystic Fibrosis
• Myriad Launches Direct to Consumer Advertising Campaign
For Breast Cancer Test
• Molecular Mining Corporation Announces the Gateway to Systems
Biology Program
• Lynx Likely Received Nasdaq Warning Letter; Stock Below
$1 for 30 Days
Tuesday
September 10, 2002
• XOMA and Biosite Resolve Patent and Licensing Disputes
•
Luminex Announces Completion of Rules-Based Medicine Sale
• BD Biosciences Gets Access to Canadian Gene and Protein
Database
Monday-Friday
September 2-6, 2002
•
GeneProt,
Duke and Novartis Collaborate for Industrial-Scale Proteomic
Study of Coronary Heart Disease
•
diaDexus and the U of Michigan Enter Proteomics Collaboration
To Identify Cancer Drug Targets and Biomarkers
• Applied Biosystems to Introduce New Protein Expression Analysis
Technology At 5th Biannual Siena Proteomics Meeting
• Luminex Announces Completion of Rules-Based Medicine Sale
• Applied
Biosystems Enhances the QSTAR LC/MS/MS System With Improved Performance
and Increased Mass Range
• Genome Quebec Makes First Investment In Private Company
• Illinois
Venture Capital Conference Selects 17 Midwest Companies to Deliver Presentations
at 2002 Event
• Cytogen To Participate In UBS Warburg Global Life Sciences
Conference In New York
• Genomics Collaborative and LION Create GCI Clinical™
Database
• Syrrx Cofounders Recognized for Innovation in Drug Discovery
With R&D 100 Award
•
SurroMed
Announces Collaboration with Lilly For Pilot BioMarker Discovery
Project: SurroMed to Undertake Proteomic and Metabolite Profiling
Analysis Of Preclinical Samples
• Bruker, PNNL Build What Surely IsnŐt Your FatherŐs
Mass Spectrometer
Friday
August 30, 2002
• San Diego Supercomputer Center Using Entropia Grid to Build
Protein-Structure Databases
Thursday
August 29, 2002
•
SYN
X Announces Q2 Financial Results
•
Genomics One issues results for Q3
•
How
Lilly Could Bloom Again
Wednesday
August 28, 2002
• The Science of Forgetfulness--Clues from a Protein
•
SYN X Executes Proteomics Deal with Multinational Company
• Applied
Biosystems to Introduce New Protein Expression Analysis Technology
At 5th Biannual Siena Proteomics Meeting
Tuesday
August 27, 2002
• Applied Biosystems and the Institute for Systems Biology
Announce Proteomics Research Collaboration
•
Cytogen Launches Second Annual `Screen, Stage and Support' Campaign
at Nasdaq to Promote Prostate Cancer Awareness
• UC
Berkeley Extension Meets Demand for Interdisciplinary Bioinformatics
Education
Monday
August 26, 2002
• Meeting Addresses Protein-Protein Interactions - Unraveling
Protein Function for Drug Target and Therapeutic Discovery
•
Bruker Daltonics Announces Stock Repurchase Program
• Maximizing
Outcomes of IT in Drug Discovery and Development: Executive Summit to
Advance the State of Healthcare
Friday
August 23, 2002
• Myriad stock tumbles in the wake of disappointing
quarterly report
Thursday
August 22, 2002
• Molecular Mining Corporation Surpasses 100 GeneLinker Placements
•
EraGen Biosciences Appoints Samraat S. Raha as Chief Business Officer
• Nutra
Pharma Corp. Completes Acquisition of Bio Therapeutics
Wednesday
August 21, 2002
•
Johns
Hopkins and Correlogic Systems Enter Into Research Agreement:
Proteomic Research to be Conducted on Inflammatory Vascular Diseases Including
Lupus, Arthritis and Vasculitis
•
Luminex
Announces License and Supply Agreement With Celera
• Myriad Reports Financial Results for Fiscal 2002
• Myriad Submits IND in Alzheimer's Disease to FDA
Tuesday
August 20, 2002
• Serenex
Raises $15 Million in Series B Financing to Leverage Proteomic and Drug
Discovery Technologies
•
ISLAR Showcases World Renown Speakers
Monday
August 19, 2002
•
New
Technology Highlight at Chips to Hits® - Microfluidics, Protein Arrays,
Semi-Conductors
•
Frost & Sullivan to Host Analyst Briefing for the Recently Released
World Life Science Mass Spectrometry Market on Thursday, August 22, 2002
• AVAKI
and NC BioGrid Co-present Grid Technology Webcast
Friday
August 16, 2002
• AxCell Biosciences Explores Pathways to Disease with IBM
Database Technology
•
Millennium
Researcher Joins NuGEN's Advisory Board
Thursday
August 15, 2002
• GlaxoSmithKline Buys Zyomyx Protein Profiling Biochip™
System
•
SurroMed
Awarded SBIR Grant from the NCI to Develop Affinity Mass Tags for Differential
Proteomics Analysis
• Ciphergen Adds Syrrx CEO to Board of Directors
• Biosite Announces Collaboration Agreement With MedImmune
•
Cellular
Genomics Opens New Drug Discovery Facility
Wednesday
August 14, 2002
•
Genomic
Solutions Reports Financial Results for Q2 and First Six Months of
2002
•
Luminex Corporation Announces Letter of Intent to Sell RBM and Management
Transition of Mark Chandler
• Cytogen Receives Notification By Nasdaq Regarding Marketplace
Rule 4450(a)(5)
Tuesday
August 13, 2002
• Applied Biosystems and Myriad Proteomics Announce
Research Collaboration to Develop Technologies and Applications for Proteomics
•
HUPO to Once Again Endorse and Co-Sponsor CHI Event
• GPC Biotech Reports Strong Results for Second Quarter and
First Half of 2002
•
Cambridge
Antibody Technology and Xerion Enter Research Collaboration
• Agilent Technologies and Accelrys Announce Software
Licensing Agreement and Technology Alliance
• Ribozyme Pharmaceuticals Announces Conference Call
• GNF and Libraria Identify Novel Chemotypes Against
Kinase Target
Monday
August 12, 2002
• ActivX Announces Publication of Papers on Activity-Based
Chemical Probes
• Marligen
Announces Acquisition of Clairus Technologies
• EraGen Welcomes CTO
Friday
August 9, 2002
• British Biotech and GeneSoft Collaborate to Discover
and Develop Novel Antibiotics
•
GeneData
Hires New CTO; Compugen Shuffles Board; and Others
Thursday
August 8, 2002
• Bio-Rad Reports Second Quarter Results
•
LSBC's Andersons Form New Institute to Probe Plasma Proteome
Wednesday
August 7, 2002
• Syrrx
Appoints Key Chemistry Talent and Completes State-of-the-Art Drug Discovery
Facility
•
Bruker AXS Launches Its Complete New X8 Product Line for Life Science
Applications at IUCr-Conference in Geneva, Switzerland
• Bruker Daltonics Q2 2002 Product Revenues Up 25%, Operating
Earnings Before Restructuring Charge Triple
• MMC
Announces the Release of GeneLinker Gold Version 2.5 and GeneLinker Platinum
Version 1.2
Tuesday
August 6, 2002
• Prolinx, Inc. Announces Expansion of Proteomic Tools Product
Line
•
Thermo
Hopes to Launch Automated, High-Throughput Molecular Spectrometer Next
Year
Monday
August 5, 2002
• Thermo Electron Highlights Capabilities and ProteomeX™
at DDT 2002
• LSBC
Announces Promising Results from Phase I Clinical Trials of Personalized
Vaccines for Non-Hodgkin's Lymphoma Patients
• Ciphergen Reports Q2 2002 Financial Results
• Syrrx Presents at DDT 2002
• Gene-IT Appoints Ronald Ranauro Executive Vice President
and General Manager
Friday
August 2, 2002
• Bruker AXS Launches New High-Throughput Screening System
for Combinatorial Analysis
•
NuGEN Awarded SBIR Grant to Develop a Rapid, High Sensitivity Test
for Anthrax
•
Bruker
Daltonics Licenses Mass Spec Patent Portfolio to Waters
Thursday
August 1, 2002
• ActivX Awarded SBIR/STTR Grant for Establishing Drug Toxicity
Profiles With Activity-Based Proteomic Technology
•
Novagen and PerkinElmer Develop an Automated Solution for Protein
Purification
• FDA
Clears Matritech's NMP22-R- BladderChek-TM- To Test Patients for
Bladder Cancer in the Doctor's Office
•
Cytogen
Reports 29 Percent Increase in Marketed Product Sales for Second Quarter
2002
• CytRx's Portfolio Company, Blizzard Genomics, Names
CEO
• Biomax Informatics Launches the Biomax Human Genome Database
Wednesday
July 31, 2002
• Xeotron Develops High Throughput Technique for Creating
Peptide Microchips
•
PerkinElmer to Highlight Novel Drug Discovery Solutions at IBC World
Congress
• ACLARA
Announces Q2 2002 Financial Results
• Lynx Reports Financial Results for the Q2 of 2002
• Matritech
Reports Q2 Financial Results
Tuesday
July 30, 2002
• Zyomyx Raises $27.0 Million in a Series E Financing
•
Lynx
Announces Initiation of Stem Cell Expression Analysis Services For Cue
Therapeutics
• Applied Biosystems Signs Global Reseller Agreement with
geneticXchange for discoveryHub Middleware Technology
• Amersham
plc Delivers Good Broad-Based First Half Growth, on Track to Meet Full
Year Targets; Financial Overview
• Longtime
Customer, Applied Biosystems, Extends Relationship With Persistence
Software
• Genicon
Sciences Launches First Nano-Based Product for Microarrays, Life Science
Research
• GenoSpectra Appoints Dr. Frank Witney Chief Executive Officer
• Matritech Announces 2002 Q2 Earnings Conference Call
Monday
July 29, 2002
•
LYNX
Announces Updated Time and Instructions for Q2 2002 Conference Call
•
Ciphergen Announces Q2 2002 Earnings and Web Cast Conference Call
Details
• Genomic Solutions Will Name New Independent Auditor
•
SYN
X Pharma to Exhibit its Research Products at the Annual Meeting and
Clinical Lab Expo
Friday
July 26, 2002
• SymyX Reports Second Quarter Financial Results
• Amersham
and Sloan-Kettering Institute in Collaboration to Scan the Human
Genome for Disease-Related Genes
Thursday
July 25, 2002
• PerkinElmer Reports Q2 2002 Results
•
Incyte Reports Financial Results for the Q2 2002
•
Applied
Biosystems profit falls, tool sales flag
• Applied Biosystems Reports Q4 and Fiscal 2002 Results
• Bruker
Daltonics to Webcast Q2 Conference Call on August 8, 2002
•
Luminex
Reports 2002 Q2 Results
• OGS
Announces Positive CPMP Opinion for Zavesca for Type 1 Gaucher Disease
in European Union
• Motorola Life Science Sells CodeLink™ Bioarray Business
to Amersham
•
Protein
Phosphatases Drug Discovery Conference to Take Place September 26-27,
2002 in Philadelphia, PA
Wednesday
July 24, 2002
• LSBC Reports Financial Results for Second Quarter 2002
• InforMax
Reports Second Quarter Results
•
OGS
Announces Decision by Ethics Committee in Israel to End Temporary Suspension
of Vevesca (OGT 918) Trials
•
Human
Genome Sciences Licenses Two Human Antibody Targets To Schering-Plough
for Drug Development
Tuesday
July 23, 2002
• LSBC Awarded $12.3 Million, Five-Year Proteomics Contract
by National Institute of Environmental Health Sciences
• Compugen
Reports Second Quarter 2002 Financial Results
• Significant
New Evidence Links Nymox's AlzheimAlert Protein to Alzheimer's
Disease Process
• DPI Reports Second Quarter 2002 Financial Results
Monday
July 22, 2002
• De Novo Pharmaceuticals and Geneformatics Announce
Drug Discovery Collaboration
•
Nanosphere
Signs Letter of Intent With Takara Bio To Form Development and
Distribution Alliance
• Biacore: Half-Year Report January - June 2002
• Affymetrix Receives NCI Grant to Uncover Hidden Genome
Activity
• NeoGenomics Forms Strategic Alliance With Florida Gulf
Coast University
Friday
July 19, 2002
• Compugen Announces Extension of Collaboration With Pfizer
•
Genetix
and the MRC Human Genome Mapping Project Resource Centre Form Collaboration
to Build a Verified Human Protein Interaction Map
• The
World Genomics Symposium and Exposition Hosts Mentoring Forum for
Graduate Students and Post-Doctorate Fellows
Thursday
July 18, 2002
• Harvard Bioscience and Genomic Solutions Announce
the Signing of a Definitive Agreement
•
Harvard Bioscience To Buy Genomic Solutions
•
Lynx
Announces Initiation of Gene Expression Analysis Services for the Ludwig
Institute for Cancer Research
• A Hard Road to New Wonder Drugs
• ZymoGenetics Receives U.S. Patent on ADAM33 Protein
•
Bio-Rad
to Report Q2 Financial Results On Thursday, August 8, 2002
• Accelrys Opens New UK Headquarters
• PerkinElmer to Hold Conference Call On Thursday, July 25,
2002
Wednesday
July 17, 2002
•
AxCell
and NCI Finalize Cooperative Research and Development Agreement
•
IEEE Computer Society to Hold First Bioinformatics Conference
• MolecularWare
Releases DigitalGenome Version 2.23
• LYNX Invites You to Participate in Its Second Quarter 2002
Conference Call
• InforMax
Announces Vector NTI Suite 7.1 for Mac OS X
Tuesday
July 16, 2002
• CombiMatrix Completes Milestone in Strategic Alliance with
Roche
•
Applied Biosystems, Spotfire Integrate Protein Analysis Software
• Hurrell
Hired To Head Indiana Proteomics Consortium
• Robert J. Rosenthal, Ph.D, Elected to Board of MolecularWare
•
BSI
Proteomics Signs Agreement With ArQule
• Japanese
Pharmaceutical Consortium Chooses Biacore to Expedite Proteomics Research
• MelTec Wins Prestigious Euro 2.3 million Research Grant
- Grant To Establish Collaborative Proteomics Research Network
• OGS and Cystic Fibrosis Foundation Therapeutics Inc.
Launch a Major Proteomics Initiative to Advance Management of Cystic Fibrosis
• Genome
Canada: Canadian Researchers Make Proteomics Breakthrough - Discovery
Being Hailed As a Paradigm Shift in Biology
• Microfluidics 2002 -- Miniaturizing, Integrating and Accelerating
Drug Discovery
Monday
July 15, 2002
•
Biochip Collaboration Between Glycominds and Schott
Receives BIRD Grant
•
Class
Action Lawsuit Against PerkinElmer on Behalf of Investors
• LSBC Announces Earnings Conference Call
• Incyte
and the U of Cambridge Report New Cause of Severe Insulin Resistance
• Esperion Announces Positive Phase I Results for RLT Peptide
(ETC-642)
• Blizzard
Genomics Names CEO; James V. Adam to Succeed Dr. Martin Blumenfeld
• Biacore: Half-year Report January - June 2002
•
Baxter
Begins Pivotal U.S., European Clinical Trials for New, Liquid Immune Globulin
Product
•
Pfizer to Acquire Pharmacia for $60 Billion In Stock
•
Structural
GenomiX Announces Drug Discovery Partnership With Asahi Kasei
|
